Wilms' Tumor Clinical Trials

A listing of Wilms' Tumor medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 27 clinical trials
Treatment of Newly Diagnosed Diffuse Anaplastic Wilms Tumors (DAWT) and Relapsed Favorable Histology Wilms Tumors (FHWT)

This phase II trial studies how well combination chemotherapy works in treating patients with newly diagnosed stage II-IV diffuse anaplastic Wilms tumors (DAWT) or favorable histology Wilms

  • 0 views
  • 28 Oct, 2022
  • 95 locations
Naxitamab for High-Risk Neuroblastoma Patients With Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone Marrow

Children and adults diagnosed with high-risk neuroblastoma patients with primary refractory disease or incomplete response to salvage treatment in bone and/or bone marrow will be treated for up to 101 weeks with naxitamab and granulocyte-macrophage colony stimulating factor (GM-CSF). Patients will be followed for up to five years after first …

bone marrow procedure
hu3f8
high-risk neuroblastoma
monoclonal antibodies
colony stimulating factor
  • 159 views
  • 07 Oct, 2022
  • 23 locations
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol

This Pediatric MATCH screening and multi-sub-study phase II trial studies how well treatment that is directed by genetic testing works in pediatric patients with solid tumors, non-Hodgkin lymphomas, or histiocytic disorders that have progressed following at least one line of standard systemic therapy and/or for which no standard treatment exists …

alpha-fetoprotein
selumetinib sulfate
chemotherapeutic agents
cns neoplasm
stem cell infusion
  • 1032 views
  • 25 Oct, 2022
  • 108 locations
Treatment of Newly Diagnosed Patient's With Wilm's Tumor Requiring Abdominal Radiation Delivered With Proton Beam Irradiation

(bilateral Wilms tumor) and specific involved surgical margins yielding no reduction in the high control rates seen with more traditional flank / whole kidney fields. Exploratory Objectives

metastasis
chemotherapeutic agents
tumor cells
cancer
MRI
  • 0 views
  • 07 Oct, 2022
  • 1 location
Pencil Beam Scanning in Patients With Renal Tumors

This is a pilot study to assess acute toxicity in patients receiving flank irradiation using proton therapy for renal tumors.

renal neoplasm
anaplasia
beam radiation
sarcoma
nephroblastoma
  • 15 views
  • 04 Oct, 2022
  • 1 location
A Phase 1/2, Open-label Study Investigating the Safety, Tolerability and Efficacy of ASP7517 as a Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors Known to Express WT1 Antigen

The purpose of this study is to evaluate the safety, tolerability, and clinical response of ASP7517, and determine the Recommended Phase 2 Dose (RP2D) and/or the Maximum Tolerated Dose (MTD) of ASP7517 when administered as a single agent and in combination with pembrolizumab. This study will also evaluate other measures …

  • 0 views
  • 25 Oct, 2022
  • 4 locations
Indocyanine Green (ICG) Guided Tumor Resection

>Rhabdomyosarcoma (RMS) Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS) Neuroblastoma Renal tumors (Only bilateral Wilms Tumor patients will be included.) Metastatic

lymphoma
cancer
solid tumor
sarcoma
solid neoplasm
  • 0 views
  • 04 Oct, 2022
  • 1 location
  • 0 views
  • 07 Oct, 2022
  • 1 location
B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)

3CAR is being done to investigate an immunotherapy for patients with solid tumors. It is a Phase I clinical trial evaluating the use of autologous T cells genetically engineered to express B7-H3-CARs for patients ≤ 21 years old, with relapsed/refractory B7-H3+ solid tumors. This study will evaluate the safety and …

platelet count
mesna
cytokines
cyclophosphamide
measurable disease
  • 0 views
  • 04 Oct, 2022
  • 1 location
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Tipifarnib in Patients With Tumors Harboring HRAS Genomic Alterations

This phase II pediatric MATCH trial studies how well tipifarnib works in treating patients with solid tumors that have recurred or spread to other places in the body (advanced), lymphoma, or histiocytic disorders, that have a genetic alteration in the gene HRAS. Tipifarnib may block the growth of cancer cells …

cancer
nervous system disorder
total body irradiation
chemotherapeutic agents
bone marrow procedure
  • 28 views
  • 20 Oct, 2022
  • 94 locations